Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global
Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website
at www.acorda.com, or you may use the link:
https://cc.talkpoint.com/gold006/060716b_ae/?entity=70_I1RTFEP
Please log in before the scheduled time of the presentations to ensure a timely connection. An archived version of this webcast
will be available until July 7, 2016 on the Investors section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and
improve the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s
disease, post-stroke walking difficulties, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to
risks and uncertainties that could cause actual results to differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among
other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process
and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to
finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other
research and development programs, including CVT-301, Plumiaz (diazepam) Nasal Spray, or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz,
any other products under development, or the products that we will acquire when we complete the Biotie transaction; the occurrence
of adverse safety events with our products; delays in obtaining or failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence on our collaborator Biogen in connection therewith; competition;
failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may
not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance
on these statements. Forward-looking statements made in this release are made only as of the date hereof, and we disclaim any
intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this
release.
Acorda Therapeutics
Felicia Vonella, 914-326-5146
fvonella@acorda.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005010/en/